No profile data available.
Xenon Pharmaceuticals Inc. (XENE) is a healthcare company in the brain and nerve treatment drugs industry, based in Burnaby, Canada, with about 358 full-time employees.
It reported revenue of $7.50 million for fiscal year 2025, and net income of -$345.91 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $3.53 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders.
Xenon Pharmaceuticals reported $7.50 million in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$3.53 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Dianthus Therapeutics, Inc. (DNTH), Acadia Pharmaceuticals Inc. (ACAD), Edgewise Therapeutics, Inc. (EWTX), Denali Therapeutics Inc. (DNLI).